Cyclacel Pharmaceuticals Inc CYCC
$6.37 $0.41 (5.98%) 1D
Last Updated: Sep 11, 12:00 AM·MUN
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Cyclacel Pharmaceuticals Inc Stock Halal?
Shariah Compliance Analysis of CYCC Stock
Germany Health Care Nano Cap No. As of September 2026, Cyclacel Pharmaceuticals Inc (CYCC) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Cyclacel Pharmaceuticals Inc does not pass Musaffa's business and financial screening criteria.
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
CYCC Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Cyclacel Pharmaceuticals Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Cyclacel Pharmaceuticals Inc (CYCC) Chart
Financial Metrics & Statements of Cyclacel Pharmaceuticals Inc (CYCC)
FAQ's for Cyclacel Pharmaceuticals Inc (CYCC)
- As of September 2026, Cyclacel Pharmaceuticals Inc CYCC is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cyclacel Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Cyclacel Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Cyclacel Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Cyclacel Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Cyclacel Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Cyclacel Pharmaceuticals Inc (CYCC)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
